Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment

Launched by EMS · May 4, 2018

Keywords

ClinConnect Summary

The clinical trial titled "Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment" is studying a new treatment for conditions called hypertriglyceridemia (high levels of triglycerides in the blood) and dyslipidemia (abnormal levels of fats in the blood). The goal is to see how effective and safe this treatment is for people who have these conditions but are at low or moderate risk for heart problems. The trial is currently looking for participants aged 18 and older, and both men and women can join as long as they meet certain health criteria.

To be eligible for the trial, participants should have been diagnosed with dyslipidemia, but cannot have certain genetic conditions or other serious health issues, such as heart disease or severe kidney problems. They should also not be using specific medications that could affect the study results. If someone decides to participate, they will need to sign a consent form, and they can expect regular check-ups to monitor their health during the study. This trial aims to find a better way to manage these conditions and improve heart health for people affected by them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants of both sexes, aged 18 years or more;
• • Participants with the diagnosis of Dyslipidemia presentinf low or intermediate cardiovascular risk, according to the Brazilian Guidelines on Dyslipidemia and Prevention of Atherosclerosis;
• • Signed consent.
• Exclusion Criteria:
• • Diagnosis of familial hypercholesterolemia and other genetic diseases;
• • Using medications that may interfere with the metabolism or serum levels of triglycerides;
• • Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;
• • Presence of concomitant cardiovascular disease, renal failure and hepatic Failure;
• • Decompensated diabetes;
• • Current smoking;
• • History hypersensitivity to the active ingredients used in the study;
• • Pregnancy or risk of pregnancy and lactating patients;
• • History of alcohol abuse or illicit drug use;
• • Participation in clinical trial in the year prior to this study.